Literature DB >> 17269451

In vitro functionality of human fetal liver cells and clonal derivatives under proliferative conditions.

Tanja Deurholt1, Lysbeth ten Bloemendaal, Aniska A Chhatta, Albert C W A van Wijk, Kees Weijer, Jurgen Seppen, Ronald P J Oude Elferink, Robert A F M Chamuleau, Ruurdtje Hoekstra.   

Abstract

Mature human hepatocytes are not suitable for large-scale in vitro applications that rely on hepatocyte function, due to their limited availability and insufficient proliferation capacity in vitro. In contrast, human fetal liver cells (HFLC) can be easily expanded in vitro. In this study we evaluated the hepatic function of HFLCs under proliferative conditions, to determine whether HFLCs can replace mature hepatocytes for in vitro applications. HFLCs were isolated from fetal livers of 16 weeks gestation. Hepatic functions of HFLCs were determined in primary culture and after expansion in vitro. Clonal derivatives were selected and tested for hepatic functionality. Results were compared to primary mature human hepatocytes in vitro. No differences were observed between primary HFLCs and mature human hepatocytes in albumin production and mRNA levels of various liver-specific genes. Ureagenesis was 4.4-fold lower and ammonia elimination was absent in HFLCs. Expanding HFLCs decreased hepatic functions and increased cell stretching. In contrast, clonal derivatives had stable functionality and morphology and responded to differentiation stimuli. Although their hepatic functions were higher than in passaged HFLCs, functionality was at least 20 times lower compared to mature human hepatocytes. HFLCs cannot replace mature human hepatocytes in in vitro applications requiring extensive in vitro expansion, because this is associated with decreased hepatic functionality. Selecting functional subpopulations can, at least partly, prevent this. In addition, defining conditions that support hepatic differentiation is necessary to obtain HFLC cultures suitable for in vitro hepatic applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17269451     DOI: 10.3727/000000006783464417

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  5 in total

1.  Hepatoblast and mesenchymal cell-specific gene-expression in fetal rat liver and in cultured fetal rat liver cells.

Authors:  Tümen Mansuroglu; József Dudás; Abderrahim Elmaouhoub; Tobias Z Joza; Giuliano Ramadori
Journal:  Histochem Cell Biol       Date:  2009-04-19       Impact factor: 4.304

2.  Multilayer nanofilms as substrates for hepatocellular applications.

Authors:  Corinne R Wittmer; Jennifer A Phelps; Christin M Lepus; William M Saltzman; Martha J Harding; Paul R Van Tassel
Journal:  Biomaterials       Date:  2008-07-23       Impact factor: 12.479

3.  Laminin alpha-3 and thrombospondin-1 differently regulate the survival and differentiation of hepatocytes and hepatic stem cells from neonatal mice.

Authors:  Shuai Zhang; Heba E Sharaf Eldin; Wei-Li Gu; Tao-Sheng Li
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  Human fetal liver cells for regulated ex vivo erythropoietin gene therapy.

Authors:  Ebtisam El Filali; Suzanne Duijst; Johan K Hiralall; Nicolas Legrand; Thomas van Gulik; Ruurdtje Hoekstra; Jurgen Seppen
Journal:  Mol Ther Methods Clin Dev       Date:  2014-03-12       Impact factor: 6.698

5.  Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes.

Authors:  Tanja Deurholt; Niek P van Til; Aniska A Chhatta; Lysbeth ten Bloemendaal; Ruth Schwartlander; Catherine Payne; John N Plevris; Igor M Sauer; Robert Afm Chamuleau; Ronald Pj Oude Elferink; Jurgen Seppen; Ruurdtje Hoekstra
Journal:  BMC Biotechnol       Date:  2009-10-21       Impact factor: 2.563

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.